Rishi Kakar, MD: EMERGENT trial, FDA Accepts Xanomeline-Trospium Application

In an interview with HCPLive, Rishi Kakar, MD, discussed how KarXT is a novel molecule unique from currently available schizophrenia treatments.

Related Keywords

,Drug Administration ,Karuna Therapeutics ,New Drug Application ,Rishi Kakar ,Xanomeline Trospium ,Karxt ,Emergent ,Emergent Trial ,Emergent Trials ,Schizophrenia ,Fda ,Fda Drug Application ,Drug Application ,Fda New Drug Application ,Pivotal Trials ,